ArticleJBRA assisted reproduction2025
PGT-A in POSEIDON Patients - perspectives and limitations.
Article in JBRA assisted reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to determine the likelihood of being able to perform PGT-A, and its results, in each POSEIDON group compared to their age-matched non-POSEIDON group.
methodsThis was a retrospective study of 4 groups of POSEIDON patients (n=824) who underwent intracytoplasmic sperm injection (ICSI) The controls were non-POSEIDON patients in two age groups (<35 and ≥35 years old; n=360).
resultsThe non-POSEIDON <35Y group had the highest number of embryos at the blastocyst stage that could be used for PGT-A (5.1±2/cycle), and the POSEIDON IV group had the fewest (0.6±0.3/cycle). Significantly fewer blastocysts were PGT-A tested in the groups with no indications for PGT-A (i.e. POSEIDON I (26%) and III (28%) and non-POSEIDON <35Y (39%)), compared to the groups with indications (i.e. POSEIDON II (69%), and IV (67%) and non POSEIDON ≥35Y (72%)). The euploidy rate was similar between groups without PGT-A indications (59%-64%) and between groups with indications (35-41%), but was significantly lower in groups with indications (p<0.001).
conclusionsPOSEIDON patients are as willing to undergo PGT-A testing as non-POSEIDON patients, despite the poor prognosis. However, the final PGT-A result is very low compared to that in non-POSEIDON patients of the same age. Failure is usually caused by the inability to perform the blastocyst biopsy due to a lack of oocytes or blastocyst-stage embryos, and to a low rate of euploidy in groups ≥35Y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.